#195 Antibiotic Duration & BALANCE Trial: Beyond Journal Club with NEJM Group
Antibiotic duration for bacteremia is something most of us learned by habit, not by trial data. In this episode, we walk through the BALANCE trial and use it as a lens to revisit how 1) host, 2) organ...
10 Joulu 202521min
#194: Severe Hypertriglyceridemia: 5 Pearls Segment
How quickly can triglycerides rise? At what threshold are patients at risk of pancreatitis or cardiovascular adverse outcomes? What do you have to rule out? How do you counsel on lifestyle changes? Wh...
3 Joulu 202538min
#193 Venous Congestion & VEXUS Interview with Dr. Ross Prager
Why is venous congestion not the same as volume overload? How can looking at IVC as well as doppler on the hepatic vein, portal vein, and/or intrarenal vein help? Can venous congestion explain someone...
19 Marras 202534min
#192 Debate on First-Line Medications for Diabetes
SGLT-2i vs. GLP-1? vs Metformin? How do you balance the cost and coverage of first-line options like metformin, SGLT-2, and GLP-1s? How do you choose between SGLT-2 and GLP-1s for comorbidities like C...
5 Marras 202536min
#191 Hepatorenal Syndrome Part 2 on Management: 5 Pearls Segment
What really works when treating HRS? Vasoconstrictors like terlipressin vs. norepinephrine vs. midodrine: how do we decide which to use? Do you give albumin? When do you give Lasix or another diuretic...
22 Loka 202530min
#190: Hepatorenal Syndrome Part 1: 5 Pearls Segment
HRS-AKI vs. other causes of AKI in cirrhosis: What do serum or urine sodium clues, albumin challenges, and shifting diagnostic criteria actually reveal about getting the diagnosis right?🔹 Sponsor: Oa...
15 Loka 202536min
#189 Bisphosphonates and Fracture Prevention Trial: Beyond Journal Club with NEJM Group
Who’s really at risk for fractures, and how should we be treating them? Most fragility fractures occur in patients without osteoporosis. Should we rethink who gets treated? And could just one or two I...
1 Loka 202530min
